JP2678605C - - Google Patents

Description

BACKGROUND OF THE INVENTION "Technical Field" The present invention is a harmful bacteria in the intestine Clostridium perfringens (Clostridium perfringens, Clostridium perfringens) selectively suppressed by intestinal flora growth of The present invention relates to an intestinal flora improving agent having an improving effect. “Prior art and its problems” In recent years, it has been known that bacterial flora (flora) in the intestine is related to human health, and interest in intestinal bacteria has been increasing. For example, Bifidobacterium is one of the main bacterial species constituting the human intestinal flora, and is known to play various beneficial physiological roles on humans and animals. Since this Bifidobacterium decreases or disappears with various diseases and aging, attempts to increase the amount of Bifidobacterium in the intestine have been made clinically, and its effectiveness has been demonstrated. For this reason, yogurt containing bifidobacteria, powdered bifidobacteria, oligosaccharides proliferating on bifidobacteria, and the like have come to be actively incorporated into normal eating habits. Among these, bifidobacteria-proliferating oligosaccharides have recently been in the spotlight, and fructooligosaccharides, soybean oligosaccharides, konjac oligosaccharides, isomaltoligosaccharides, galacto-oligosaccharides, and the like are successively introduced as those having a bifidobacterial growth effect. Some of them are commercially available as health food materials. On the other hand, C. perfringens is also one of the bacterial species that make up the intestinal flora, but has a harmful physiological activity contrary to Bifidobacterium, and some of them are also known to cause food poisoning. I have. Also, the number of C. perfringens increases with aging, and the detection rate and the number of bacteria tend to increase with age, suggesting a relationship with aging.
In other words, as the number of C. perfringens increases, intestinal spoilage increases, and a large amount of harmful substances such as ammonia, hydrogen sulfide, amines, phenols, and indole are produced, and these are absorbed by the host, leading to aging. It is thought that it will haveten. In addition, when the number of C. perfringens increases, the number of bifidobacteria decreases and the intestinal pH shifts to the alkaline side, so that the absorption of ammonia generated in the intestine is promoted, and the activity of amino acid decarboxylase is increased. It is believed that various deleterious phenomena occur, such as increased production. Despite the fact that C. perfringens has such a harmful effect, there has been little research on actively suppressing C. perfringens at present. [Object of the invention] An object of the present invention is to improve the intestinal flora by suppressing the growth of Bifidobacterium, which is a useful bacterium, by selectively suppressing the growth of B. perfringens and improving the intestinal flora. To provide an agent. "Constitution of the Invention" The present inventors have been studying the effects of glucose on the intestinal microflora of linearly linked oligosaccharides for many years, and in the process, oligosaccharides of trisaccharide to heptasaccharide are converted. ,
The present inventors have found that it is possible to improve the intestinal flora by suppressing the growth of harmful bacteria, C. perfringens, without suppressing the growth of bifidobacteria, which is a useful intestinal bacterium, and completed the present invention. That is, the present onset Ming, C. perfringens, characterized in that it contains maltotriose, maltotetraose, maltopentaose, maltohexaose, selected from maltoheptaose one or two or more thereof as the main component Choose the growth of
It is an intestinal flora improving agent that can be selectively suppressed. As a result of a human body administration test as described later, it was confirmed that the oligosaccharide had an effect of selectively suppressing the growth of Bacillus cerevisiae without suppressing the growth of Bifidobacterium. Therefore, the intestinal flora can be improved by taking these oligosaccharides. The intestinal flora improving agent of the present invention is selected from maltotriose, maltotetraose, maltopentaose, maltohexaose, and maltoheptaose.
Of the above-mentioned oligosaccharides, any one may be used as a main component, or a mixture containing two or more types as a main component may be used. However, according to the study of the present inventors, among these oligosaccharides, maltotetraose (G4) was particularly effective in improving the intestinal bacterial flora. The method for producing the oligosaccharide used in the present invention is not particularly limited, and any known method can be employed. For example, maltotriose (G3) can be obtained by a method of hydrolyzing pullulan with pullulanase, a method of reacting starch with amylase produced by Streptomyces griseus, or the like. In addition, maltotriose (G3) can be obtained as a by-product during the production of maltose (G2) by the fractionation method, which is advantageous in terms of production cost, and those having a maltriose (G3) content of 45% are commercially available. ing. In addition, maltotetraose (G4) is added to starch by Pseudomonas stutzeri (P
seudomonas stuzeri) and Pseudomonas sacchophila (Pseudomonas sacch
arophila) to produce maltotetraose-producing enzyme. More specifically, a method as disclosed in Japanese Patent Application No. 62-171608 already proposed by the present applicant can be employed. That is, this is a method in which malttetraose-forming enzyme and, if necessary, a debranching enzyme are allowed to act on a liquefied starch solution to carry out a saccharification reaction, or to fractionate and purify the saccharification reaction. In this method, the content of maltotetraose is 70 to 95% by weight, the content of sugars such as maltopentaose and maltohexaose is not less than 12% by weight, and the content of glucose, maltose and maltotriose is not more than 12% by weight. A mixture having a sugar content of 18% by weight or less is obtained. In the present invention, this mixture may be used as it is, or each oligosaccharide may be further purified from this mixture and used. Also, maltopentaose (G5) and maltohexaose (G6) are, for example, starch,
Bacillus Richiniforumisu (B. licheniformis), Aero Arthrobacter Earogene <br/> scan (Aerobacter aerogenes) or the like is obtained by operating the amylase specifically produced. Maltoheptaose (G7) can be obtained together with other oligos and the like by the method described in the aforementioned Japanese Patent Application No. 62-171608, and can be purified and used as necessary. The intestinal flora-improving agent of the present invention comprising the above oligosaccharide improves the intestinal flora by, for example, ingesting as it is or by adding it to bread, cake, cookie, candy, cream, boiled down, etc. Effect can be obtained. Oligosaccharides are also effective as a low-potency sweetener because the sweetness decreases as the degree of polymerization increases, and maltotriose is also effective as a humectant because of its high hygroscopicity. It is effective in preventing aging of sugar, preventing crystallization of sugar, and polishing the surface of food. Therefore, the intestinal flora improving agent of the present invention can also provide the above-described effects of improving taste and physical properties by being added to various foods. Incidentally, the intestinal flora improving agent of the present invention comprising the oligosaccharide, for example, fructooligosaccharides having a bifidobacterial growth effect, soybean oligosaccharides, konjac oligosaccharides, isomaltoligosaccharides, by using in combination with galacto-oligosaccharides, The effect of the present invention, that is, the effect of suppressing the growth of C. perfringens, which is a harmful bacterium in the intestine, and the effect of multiplying the useful bacterium Bifidobacterium can be obtained. "Examples of the Invention" Example Potato starch was liquefied according to a conventional method to obtain a liquefied starch solution having a DE of 1 or less and a concentration of 10% by weight. To this, add 2 units of maltotetraose producing enzyme per 1 g of solid substrate,
After adjusting to pH 6.5 and reacting at 55 ° C. for 10 hours, diatomaceous earth filtration was performed to remove impurities. Here, one unit is defined as pH 7, temperature, using reduced soluble starch as a substrate.
This is the amount of enzyme that cuts 1 μmol of glucosidic bonds per minute by performing an enzyme reaction at 40 ° C. Then, flat membrane UF device (DDS's trade name "Lab module"), molecular weight cut-2000, fitted with ultrafiltration membrane with a membrane area 0.36 m ^2, the above-described reaction solution at 55 ° C. 10
After circulating for a time, the membrane treatment was performed together with the saccharification reaction. As a result of analyzing the sugar composition of the permeated liquid thus obtained by liquid chromatography, G1; 1.0, G2; 4.6, G3; 9.3, G4
; 54.1, G5; 1.2, G6; 0.8, G7 or higher sugars; 29.0 (all by weight). This permeated solution was powdered to obtain an intestinal flora improving agent according to the present invention. Test Example Using the oligosaccharide powder containing 54% of maltotetraose obtained in the above example, a human body administration test was conducted to examine the effect on the intestinal flora. That is, seven healthy men sampled twice during the control period of normal eating habits, and then ingested the above oligosaccharide powder at a rate of 30 g / day for 10 days. Was sampled twice. Thereafter, administration of the oligosaccharide powder was stopped, and sampling was performed twice on the seventh and tenth days after the stop. At a total of six samplings, the intestinal flora was searched using Mitsuoka's method ("The World of Intestinal Bacteria", Separation and Identification of Anaerobic Bacteria, Toshimitsu Mitsuoka, Horabunsha, 1984), and bifidobacteria and Welsh The number of bacteria, the detection rate, and the ratio to the total number of bacteria were examined. Table 1 shows the results. Table 1 shows the results divided into three periods before, during and after administration of the oligosaccharide powder. In addition, since sampling was performed twice in each period, the number of bacteria shows the average of a total of 14 samplings, and the detection rate was
It shows how many of the 14 samplings were detected. As shown in Table 1, the ingestion of the oligosaccharide powder resulted in
Although no change was observed in C. perfringens, no change was detected in C. perfringens. [Effect of the Invention] As described above, the intestinal flora improving agent of the present invention inhibits the growth of Bifidobacterium without inhibiting the growth of Bifidobacterium, so that the intestinal flora can be improved. And contribute to maintaining human health.

Claims (1)

Claims (1) It is characterized by containing, as a main component, one or a mixture of two or more selected from maltotriose, maltotetraose, maltopentaose, maltohexaose, and maltoheptaose. An intestinal flora improving agent that selectively suppresses the growth of C. perfringens . (2) One or more selected from maltotriose, maltotetraose, maltopentaose, maltohexaose, and maltoheptaose, and fructooligosaccharides, soybean oligosaccharides, konjac oligosaccharides, isomaltoligosaccharides, and galactooligosaccharides The intestinal flora improving agent according to claim 1, comprising one or more selected from the group consisting of: